Our results demonstrate a successful clinical application of the PU-FITC-binding assay in a post-transplant, relapsed AML patient with PML-SYK fusion whose tumor cells demonstrated epichaperome abundance. This evidence concerns the gene PML and acute myeloid leukemia.